Is Diamondback Energy a Good Stock to Buy?
Diamondback Energy (FANG) is a lesser-known diamond in the rough…
Buy
64
DSRLF Quote, Financials, Valuation and Earnings
Last price:
$109.6000
Seasonality move
:
8.94%
Day range:
$109.6000 - $109.6000
52-week range:
$88.4500 - $109.6000
Dividend yield:
1.14%
P/E ratio:
28.54x
P/S ratio:
4.57x
P/B ratio:
3.41x
Volume:
--
Avg. volume:
6
1-year change:
18.85%
Market cap:
$5.9B
Revenue:
$1.3B
EPS (TTM):
$3.84
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Diasorin SpA has -- downside to fair value with a price target of -- per share.
DSRLF vs. S&P 500
-
Over the past 5 trading days, Diasorin SpA has underperformed the S&P 500 by -1.97% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Diasorin SpA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Diasorin SpA has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Diasorin SpA reported revenues of $315.6M.
Earnings Growth
-
Diasorin SpA has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Diasorin SpA reported earnings per share of $0.93.
Enterprise value:
6.7B
EV / Invested capital:
--
Price / LTM sales:
4.57x
EV / EBIT:
24.01x
EV / Revenue:
5.24x
PEG ratio (5yr expected):
1.02x
EV / Free cash flow:
17.23x
Price / Operating cash flow:
20.64x
Enterprise value / EBITDA:
24.01x
Gross Profit (TTM):
$838.6M
Return On Assets:
5.86%
Net Income Margin (TTM):
16.02%
Return On Equity:
10.8%
Return On Invested Capital:
9.02%
Operating Margin:
21.95%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.5B | $1.3B | $1.3B | $294M | $315.6M | |
| Gross Profit | $994.9M | $826.4M | $838.6M | $181.8M | $206.8M | |
| Operating Income | $435.6M | $272.2M | $282.8M | $52.3M | $69.3M | |
| EBITDA | $413.2M | $257.1M | $278.9M | $52.3M | $69.3M | |
| Diluted EPS | $5.70 | $3.00 | $3.84 | $0.51 | $0.93 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | -- | |
| Total Assets | -- | -- | $2.5B | -- | -- | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | $903.9M | -- | -- | |
| Total Equity | $1.1B | $1.4B | $1.6B | $1.6B | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $410.6M | $337.4M | -- | $91.3M | $74M | |
| Cash From Investing | -$244.6M | -$31.5M | -- | -$53.3M | -$13.4M | |
| Cash From Financing | -$351.2M | -$255.5M | -- | $52.7M | $71.4M | |
| Free Cash Flow | $410.6M | $214.8M | -- | -$31.3M | -- | |
DSRLF
Sector
Market Cap
$5.9B
$39.2M
Price % of 52-Week High
100%
45.99%
Dividend Yield
1.14%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
18.85%
-38.63%
Beta (5-Year)
0.178
0.774
Dividend yield:
1.14%
Annualized payout:
$1.25
Payout ratio:
31.17%
Growth streak:
2 years
Technicals
8-day SMA
Sell
Level
$109.6000
200-day SMA
Buy
Level
$103.7022
Bollinger Bands (100)
Buy
Level
103.3547 - 109.1747
Chaikin Money Flow
Buy
Level
2.1K
20-day SMA
Buy
Level
$108.6660
Relative Strength Index (RSI14)
Buy
Level
78.7998
ADX Line
Buy
Level
64.256
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$105.4243
MACD (12, 26)
Buy
Level
1.3420
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
84.7K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1521)
Buy
CA Score
(Annual)
Level (-0.1915)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-0.1712)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics--testing done on samples taken from the human body, such as blood and issue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (55% of sales) and molecular diagnostics (35%) and has a total installed base of over 9,000 diagnostic systems. Licensed technologies contribute the remaining 10% of total sales, DiaSorin has a strong presence in Europe, the Middle East, and Africa; the region accounts for the largest portion of company revenue (44%), followed by North America (41%), Asia-Pacific (11%), and Latin America (4%).
Stock Forecast FAQ
In the current month, DSRLF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DSRLF average analyst price target in the past 3 months is --.
-
Where Will Diasorin SpA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Diasorin SpA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Diasorin SpA?
Analysts are divided on their view about Diasorin SpA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Diasorin SpA is a Sell and believe this share price will rise from its current level to --.
-
What Is Diasorin SpA's Price Target?
The price target for Diasorin SpA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DSRLF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Diasorin SpA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of DSRLF?
You can purchase shares of Diasorin SpA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Diasorin SpA shares.
-
What Is The Diasorin SpA Share Price Today?
Diasorin SpA was last trading at $109.6000 per share. This represents the most recent stock quote for Diasorin SpA. Yesterday, Diasorin SpA closed at $109.6000 per share.
-
How To Buy Diasorin SpA Stock Online?
In order to purchase Diasorin SpA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is up 0.24% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is down 1.45% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 3.19% over the past day.
